Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

Executive Summary

Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.

You may also be interested in...



Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE

Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.

AZ On The Rise In All Regions And Therapy Areas

The drug major's Q2 sales soared past consensus forecasts, driven by its three soon-to-be oncology blockbusters – Tagrisso, Imfinzi and Lynparza.

AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics

AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel